Report: Sigma-Tau may sell a stake in company

Bloomberg cites sources close to Italy's Sigma-Tau who say that the company is considering selling a stake in the biotech following the death of its founder. Four Partners is advising the company, which is reportedly considering a deal that would value the company at $1.4 billion. Sigma-Tau has a pipeline of drugs in development for rare and neglected ailments. Story

Suggested Articles

Xcovery's ALK inhibitor shrank tumors in 75% of lung cancer patients, compared to 67% for Pfizer's Xalkori, the first FDA-approved drug of that class.

The FDA accepted the regulatory filing for Biogen's once-failed Alzheimer's drug, aducanumab, with plans to decide its fate by March 7, 2021.

Alexion named a chief diversity officer, while COVID-19 vaccine player has two new members of its C-suite.